 

Active ingredient: Aspirin and Oxycodone Hydrochloride 

Aspirin; Oxycodone Hydrochloride and Oxycodone Terephthalate 

 

Form/Route: Tablet/Oral 

 

Recommended studies: 

 

Aspirin and Oxycodone Hydrochloride Tablets and Aspirin, Oxycodone Hydrochloride and 
Oxycodone Terephthalate Tablets are a DESIi effective drug for which there are no known or 
suspected bioequivalence problems, and as such is rated “AA” in the FDA/CDER’s Approved 
Drug Products with Therapeutic Equivalence Evaluations (“Orange Book”). 

 

______________________________________________________________________________ 

 

Analytes to measure (in appropriate biological fluid): Not Applicable 

 

Bioequivalence based on (90% CI): Not Applicable 

 

Waiver request of in-vivo testing: 325 mg/4.8355 mg and 325 mg/4.5 mg/0.38 mg pursuant to 
21 CFR 320.22 (c) provided that the in-vitro dissolution profiles of the proposed product are 
comparable to those of the reference product. 

 

Dissolution test method and sampling times: 

 

Please note that a Dissolution Methods Database is available to the public at the OGD website 
at http://www.accessdata.fda.gov/scripts/cder/dissolution/. Please find the dissolution 
information for this product at this website. Please conduct comparative dissolution testing on 12 
dosage units each of the test and reference products. Specifications will be determined upon 
review of the application. 

 

 

i Drug Efficacy Study Implementation 


